### Learner Notification

**MED Learning Group**

**Take Home Messages for Clinical Practice: Transforming First-Line Treatment of Advanced Non-Small Cell Lung Cancer**

**June 4, 2023**

**Online**

**Acknowledgement of Financial Commercial Support**

Regeneron Pharmaceuticals, Inc.

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Joint Accreditation Statement**

A picture containing drawing

Description automatically generatedIn support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum 1.00 ANCC contact hours.

###### Objectives - After Attending This Program You Should Be Able To

1. Evaluate the application of clinical practice guidelines to the treatment of patients with advanced NSCLC and no targetable mutations.
2. Review the management of immune-related adverse events in patients with NSCLC treated with immunotherapies.
3. Discuss the trials findings for first-line, immunotherapy agents both as monotherapy and in combination in the management of patients with advanced NSCLC.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Commercial Interest: Relationship** |
| Debora S. | Bruno | Amgen, Bristol Meyers Squibb, Novartis, Eli Lilly, Daiichi-Sankyo, AstraZeneca, Mirati Therapeutics: Consultant, Bristol Meyers Squibb, Dragonfly Therapeutics, Mirati Therapeutics, Daiichi-Sankyo, AstraZeneca, Genentech, Seagen: Contracted Research |
| David P. | Carbone | GSK, Iovance Biotherapeutics, Janssen, Jazz, JNJ, Merck/EMD Serono, Merck KGgA, Mirati, Novartis, Regeneron, Sanofi, Roche Taiwan, AZ, Pfizer, Arcus Biosciences, Roche, BMS Israel, AbbVie, MSD, Pfizer Egypt, Genentech: Contracted Research |
| Millena | De Brito | NA |
| Matthew | Frese | NA |
| Christina | Gallo | NA |
| Deb | Gordon | NA |
| Amanda | Jenkins | NA |
| Melissa A. | Johnson | NA |
| Nicole | Longo | NA |
| Aimee | Meissner | NA |
| Jo | Shultz | NA |
| Lauren | Welch | NA |

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)